Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

2018150 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov identifier: NCT02048709 .

Good health and well-being

Published in: Journal for ImmunoTherapy of Cancer

Volume 6, Issue 1, pp. 61-61

Field-Weighted Citation Impact: 4.81